Sinil Pharmaceutical Co. Ltd (012790) — Financial Flexibility Index
Sinil Pharmaceutical Co. Ltd (012790) has a Financial Flexibility Index of 0.16x as of September 2025. Free cash flow of ₩2.84 Billion (operating CF ₩2.62 Billion minus capex ₩213.15 Million) represents 0% of total liabilities (₩18.23 Billion). Also explore 012790 net assets growth trend to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Sinil Pharmaceutical Co. Ltd Financial Flexibility Index (2014–2024)
Historical Financial Flexibility Index trend for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Check 012790 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year free cash flow to debt coverage for Sinil Pharmaceutical Co. Ltd. For the full company profile including market capitalisation, see 012790 market cap.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.61x | ₩31.16 Billion | ₩22.69 Billion | ₩19.36 Billion | ▲ +0.7% |
| 2023 | 1.60x | ₩28.08 Billion | ₩15.15 Billion | ₩17.56 Billion | ▲ +35.8% |
| 2022 | 1.18x | ₩23.02 Billion | ₩13.69 Billion | ₩19.55 Billion | ▲ +25.5% |
| 2021 | 0.94x | ₩14.79 Billion | ₩11.16 Billion | ₩15.78 Billion | ▼ -18.2% |
| 2020 | 1.15x | ₩19.86 Billion | ₩11.06 Billion | ₩17.33 Billion | ▼ -13.7% |
| 2019 | 1.33x | ₩22.04 Billion | ₩12.31 Billion | ₩16.59 Billion | ▼ -15.0% |
| 2018 | 1.56x | ₩17.53 Billion | ₩9.19 Billion | ₩11.22 Billion | ▲ +0.3% |
| 2017 | 1.56x | ₩18.05 Billion | ₩8.67 Billion | ₩11.59 Billion | ▲ +15.4% |
| 2016 | 1.35x | ₩14.66 Billion | ₩12.09 Billion | ₩10.86 Billion | ▼ -20.1% |
| 2015 | 1.69x | ₩15.37 Billion | ₩9.56 Billion | ₩9.09 Billion | ▲ +32.3% |
| 2014 | 1.28x | ₩11.57 Billion | ₩9.33 Billion | ₩9.06 Billion | — |